Cardiome Pharma (CRME) Says New Data Presented at ESC Highlights Clinical Benefit of BRINAVESS
Tweet Send to a Friend
Cardiome Pharma Corp. (NASDAQ: CRME) today announced the presentation of new data for BRINAVESS (vernakalant hydrochloride, IV), the Company's antiarrhythmic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
